Disclosed herein are carboxyl group containing perfluoropolyether compounds of formula (I): RfX.sup.1X.sup.2 (I), wherein the groups Rf, X.sup.1 and X.sup.2 are defined herein. Also disclosed are methods of preparing and using perfluoropolyether compounds.

Compounds of formula (I):

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Compounds of formula (I):

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Disclosed are benzoate derivatives. Provided is a compound having a formula selected from the group consisting of following structures. The compound can be used for quality control over a 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride product, and also for inflammation diminishment ##STR00001##

Disclosed are benzoate derivatives. Provided is a compound having a formula selected from the group consisting of following structures. The compound can be used for quality control over a 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride product, and also for inflammation diminishment ##STR00001##

New regulator compounds for a novel polymerization process for vinyl monomers, which yields polymers with improved control over composition and nearly full to full conservation of architectural integrity up to high conversion. The regulator compounds are defined by according to anyone of the Formulas 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H and 1I:

##STR00001## wherein R.sup.1 stands for an optionally substituted secondary or tertiary alkyl or secondary or tertiary aralkyl; Z.sup.1 stands for CN or a carboxylic acid ester of formula C(O)OR.sup.21; Z.sup.2 may be chosen from the group of CN, carboxylic acid, salts of carboxylic acids, carboxylic acid ester, carboxylic acid amides, (hetero)aryl, alkenyl and halogen; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently chosen from the group of H, alkyl, aralkyl, (hetero)aryl, CN and carboxylic acid ester of formula C(O)OR.sup.22; R.sup.7 stands for a primary alkyl or primary aralkyl, CN or hydrogen; Y stands for a bridging group and n is 2, 3, 4, 5 or 6; in case R.sup.1 stands for tertiary alkyl or tertiary aralkyl, R.sup.6 stands for a primary alkyl or primary aralkyl, CN or a carboxylic acid ester of formula C(O)OR.sup.26; in case R.sup.1 stands for a secondary alkyl or secondary aralkyl, R.sup.6 stands for a primary or secondary alkyl or primary or secondary aralkyl, CN, a carboxylic acid ester of formula C(O)OR.sup.26 or a phosphonic acid ester of formula P(O)(OR.sup.27).sub.2, a (hetero)aryl or an alkenyl; R.sup.21, R.sup.22, R.sup.26 and R.sup.27 each independently stand for alkyl or aralkyl having from 1-30 carbon atoms, optionally containing heteroatoms.

New regulator compounds for a novel polymerization process for vinyl monomers, which yields polymers with improved control over composition and nearly full to full conservation of architectural integrity up to high conversion. The regulator compounds are defined by according to anyone of the Formulas 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H and 1I:

##STR00001## wherein R.sup.1 stands for an optionally substituted secondary or tertiary alkyl or secondary or tertiary aralkyl; Z.sup.1 stands for CN or a carboxylic acid ester of formula C(O)OR.sup.21; Z.sup.2 may be chosen from the group of CN, carboxylic acid, salts of carboxylic acids, carboxylic acid ester, carboxylic acid amides, (hetero)aryl, alkenyl and halogen; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently chosen from the group of H, alkyl, aralkyl, (hetero)aryl, CN and carboxylic acid ester of formula C(O)OR.sup.22; R.sup.7 stands for a primary alkyl or primary aralkyl, CN or hydrogen; Y stands for a bridging group and n is 2, 3, 4, 5 or 6; in case R.sup.1 stands for tertiary alkyl or tertiary aralkyl, R.sup.6 stands for a primary alkyl or primary aralkyl, CN or a carboxylic acid ester of formula C(O)OR.sup.26; in case R.sup.1 stands for a secondary alkyl or secondary aralkyl, R.sup.6 stands for a primary or secondary alkyl or primary or secondary aralkyl, CN, a carboxylic acid ester of formula C(O)OR.sup.26 or a phosphonic acid ester of formula P(O)(OR.sup.27).sub.2, a (hetero)aryl or an alkenyl; R.sup.21, R.sup.22, R.sup.26 and R.sup.27 each independently stand for alkyl or aralkyl having from 1-30 carbon atoms, optionally containing heteroatoms.

-Substituted -amino acids, -substituted -amino acid derivatives, and -substituted -amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the -substituted -amino acid derivatives and -substituted -amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

-Substituted -amino acids, -substituted -amino acid derivatives, and -substituted -amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the -substituted -amino acid derivatives and -substituted -amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The -substituted -amino acid derivatives and -substituted -amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The -substituted -amino acid derivatives and -substituted -amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

Compounds of formula (I): where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. ##STR00001##